BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Llovet JM, De Baere T, Kulik L, Haber PK, Greten TF, Meyer T, Lencioni R. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2021;18:293-313. [PMID: 33510460 DOI: 10.1038/s41575-020-00395-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 14.0] [Reference Citation Analysis]
Number Citing Articles
1 Liu JKH, Irvine AF, Jones RL, Samson A. Immunotherapies for hepatocellular carcinoma. Cancer Med 2021. [PMID: 34953051 DOI: 10.1002/cam4.4468] [Reference Citation Analysis]
2 Yuan M, Shong K, Li X, Ashraf S, Shi M, Kim W, Nielsen J, Turkez H, Shoaie S, Uhlen M, Zhang C, Mardinoglu A. A Gene Co-Expression Network-Based Drug Repositioning Approach Identifies Candidates for Treatment of Hepatocellular Carcinoma. Cancers 2022;14:1573. [DOI: 10.3390/cancers14061573] [Reference Citation Analysis]
3 Wu X, Ge L, Shen G, He Y, Xu Z, Li D, Mu C, Zhao L, Zhang W. 131I-Labeled Silk Fibroin Microspheres for Radioembolic Therapy of Rat Hepatocellular Carcinoma. ACS Appl Mater Interfaces 2022;14:21848-59. [PMID: 35507826 DOI: 10.1021/acsami.2c00211] [Reference Citation Analysis]
4 Brown ZJ, Hewitt DB, Pawlik TM. Experimental drug treatments for hepatocellular carcinoma: Clinical trial failures 2015 to 2021. Expert Opin Investig Drugs 2022. [PMID: 35580650 DOI: 10.1080/13543784.2022.2079491] [Reference Citation Analysis]
5 Xing R, Gao J, Cui Q, Wang Q. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma. Front Immunol 2021;12:783236. [PMID: 34899747 DOI: 10.3389/fimmu.2021.783236] [Reference Citation Analysis]
6 Ke Q, Xin F, Fang H, Zeng Y, Wang L, Liu J. The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review. Front Immunol 2022;13:913464. [DOI: 10.3389/fimmu.2022.913464] [Reference Citation Analysis]
7 Sun R, Dai J, Ling M, Yu L, Yu Z, Tang L. Delivery of triptolide: a combination of traditional Chinese medicine and nanomedicine. J Nanobiotechnology 2022;20:194. [PMID: 35443712 DOI: 10.1186/s12951-022-01389-7] [Reference Citation Analysis]
8 Elkhadragy L, Dasteh Goli K, Totura WM, Carlino MJ, Regan MR, Guzman G, Schook LB, Gaba RC, Schachtschneider KM. Effect of CRISPR Knockout of AXIN1 or ARID1A on Proliferation and Migration of Porcine Hepatocellular Carcinoma. Front Oncol 2022;12:904031. [DOI: 10.3389/fonc.2022.904031] [Reference Citation Analysis]
9 Jiaze Y, Sinan H, Minjie Y, Yongjie Z, Nan D, Liangwen W, Wen Z, Jianjun L, Zhiping Y. Rcl1 suppresses tumor progression of hepatocellular carcinoma: a comprehensive analysis of bioinformatics and in vitro experiments. Cancer Cell Int 2022;22:114. [PMID: 35264160 DOI: 10.1186/s12935-022-02533-x] [Reference Citation Analysis]
10 Regmi P, He Z, Lia T, Paudyal A, Li F. N7-Methylguanosine Genes Related Prognostic Biomarker in Hepatocellular Carcinoma. Front Genet 2022;13:918983. [DOI: 10.3389/fgene.2022.918983] [Reference Citation Analysis]
11 Su TH, Hsu SJ, Kao JH. Paradigm shift in the treatment options of hepatocellular carcinoma. Liver Int 2021. [PMID: 34515412 DOI: 10.1111/liv.15052] [Reference Citation Analysis]
12 Ginès P, Krag A, Abraldes JG, Solà E, Fabrellas N, Kamath PS. Liver cirrhosis. Lancet 2021;398:1359-76. [PMID: 34543610 DOI: 10.1016/S0140-6736(21)01374-X] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
13 Zhou ZY, Liu SR, Xu LB, Liu C, Zhang R. Clinicopathological and Prognostic Value of Programmed Cell Death 1 Expression in Hepatitis B Virus-related Hepatocellular Carcinoma: A Meta-analysis. J Clin Transl Hepatol 2021;9:889-97. [PMID: 34966652 DOI: 10.14218/JCTH.2021.00056] [Reference Citation Analysis]
14 Fang C, Liu S, Feng K, Huang C, Zhang Y, Wang J, Lin H, Wang J, Zhong C. Ferroptosis-related lncRNA signature predicts the prognosis and immune microenvironment of hepatocellular carcinoma. Sci Rep 2022;12:6642. [PMID: 35459272 DOI: 10.1038/s41598-022-10508-1] [Reference Citation Analysis]
15 Zhang Y, Zhang X, Kuang M, Yu J. Emerging insights on immunotherapy in liver cancer. Antioxid Redox Signal 2022. [PMID: 35754339 DOI: 10.1089/ars.2022.0047] [Reference Citation Analysis]
16 Cai Q, Zhu M, Duan J, Wang H, Chen J, Xiao Y, Wang Y, Wang J, Yu X, Yang H. Comprehensive Analysis of Immune-Related Prognosis of TK1 in Hepatocellular Carcinoma. Front Oncol 2022;11:786873. [DOI: 10.3389/fonc.2021.786873] [Reference Citation Analysis]
17 Ren L, Chen D, Xu W, Xu T, Wei R, Suo L, Huang Y, Chen H, Liao W. Predictive potential of Nomogram based on GMWG for patients with hepatocellular carcinoma after radical resection. BMC Cancer 2021;21:817. [PMID: 34266388 DOI: 10.1186/s12885-021-08565-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Trotovšek B, Djokić M, Čemažar M, Serša G. New era of electrochemotherapy in treatment of liver tumors in conjunction with immunotherapies. World J Gastroenterol 2021; 27(48): 8216-8226 [DOI: 10.3748/wjg.v27.i48.8216] [Reference Citation Analysis]
19 Fu J, Lei X. Identification of the Immune Subtype of Hepatocellular Carcinoma for the Prediction of Disease-Free Survival Time and Prevention of Recurrence by Integrated Analysis of Bulk- and Single-Cell RNA Sequencing Data. Front Immunol 2022;13:868325. [DOI: 10.3389/fimmu.2022.868325] [Reference Citation Analysis]
20 Silk T, Silk M, Wu J. Up to seven criteria in selection of systemic therapy for hepatocellular carcinoma. World J Gastroenterol 2022; 28(23): 2561-2568 [DOI: 10.3748/wjg.v28.i23.2561] [Reference Citation Analysis]
21 Meng W, Yang B, Huang B, Chen C, Zhu J, Jian D, Zhong L, Wang D, Li C, Bai L. Impact of preoperative transcatheter rectal arterial chemoembolization with concurrent chemoradiotherapy on surgery and prognosis of patients with locally advanced rectal cancer. J Surg Oncol 2021;124:1451-8. [PMID: 34510454 DOI: 10.1002/jso.26673] [Reference Citation Analysis]
22 Hou Z, Liu J, Jin Z, Qiu G, Xie Q, Mi S, Huang J. Use of chemotherapy to treat hepatocellular carcinoma. Biosci Trends 2022. [PMID: 35173139 DOI: 10.5582/bst.2022.01044] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Shah MB, Villagomez Rubio DA, Orozco G, Desai S, Ancheta A, Gupta M, Mei X, Evers BM, Gedaly R, Cannon RM. Outcomes in Elderly Patients Undergoing Liver Transplantation Compared with Liver-Directed Ablative Therapy in Early-Stage Hepatocellular Carcinoma. Journal of the American College of Surgeons 2022;234:892-9. [DOI: 10.1097/xcs.0000000000000135] [Reference Citation Analysis]
24 Llovet JM, Vogel A, Madoff DC, Finn RS, Ogasawara S, Ren Z, Mody K, Li JJ, Siegel AB, Dubrovsky L, Kudo M. Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment. Cardiovasc Intervent Radiol 2022. [PMID: 35119481 DOI: 10.1007/s00270-021-03031-9] [Reference Citation Analysis]
25 Bu X, Ma L, Liu S, Wen D, Kan A, Xu Y, Lin X, Shi M. A novel qualitative signature based on lncRNA pairs for prognosis prediction in hepatocellular carcinoma. Cancer Cell Int 2022;22:95. [PMID: 35193591 DOI: 10.1186/s12935-022-02507-z] [Reference Citation Analysis]
26 Jin W, Liang Y, Li S, Lin G, Liang H, Zhang Z, Zhang W, Nie R. MiR-513b-5p represses autophagy during the malignant progression of hepatocellular carcinoma by targeting PIK3R3. Aging (Albany NY) 2021;13:16072-87. [PMID: 34120890 DOI: 10.18632/aging.203135] [Reference Citation Analysis]
27 Inoue T, Naitoh I, Kitano R, Ibusuki M, Kobayashi Y, Sumida Y, Nakade Y, Ito K, Yoneda M. Endobiliary Radiofrequency Ablation Combined with Gemcitabine and Cisplatin in Patients with Unresectable Extrahepatic Cholangiocarcinoma. Current Oncology 2022;29:2240-51. [DOI: 10.3390/curroncol29040182] [Reference Citation Analysis]
28 Preel A, Hermida M, Allimant C, Assenat E, Guillot C, Gozzo C, Aho-Glele S, Pageaux GP, Cassinotto C, Guiu B. Uni-, Bi- or Trifocal Hepatocellular Carcinoma in Western Patients: Recurrence and Survival after Percutaneous Thermal Ablation. Cancers (Basel) 2021;13:2700. [PMID: 34070800 DOI: 10.3390/cancers13112700] [Reference Citation Analysis]
29 Qin J, Huang Y, Zhou H, Yi S. Efficacy of Sorafenib Combined With Immunotherapy Following Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma: A Propensity Score Analysis. Front Oncol 2022;12:807102. [DOI: 10.3389/fonc.2022.807102] [Reference Citation Analysis]
30 Dai T, Ye L, Yu H, Li K, Li J, Liu R, Lu X, Deng M, Li R, Liu W, Yang Y, Wang G. Regulation Network and Prognostic Significance of Aldo-Keto Reductase (AKR) Superfamily Genes in Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:997-1021. [PMID: 34513744 DOI: 10.2147/JHC.S323743] [Reference Citation Analysis]
31 Wu H, Xu XF, Zhu JQ, Wang MD, Li C, Liang L, Xing H, Wu MC, Shen F, Huang DS, Yang T. Mesoporous Silica Nanoparticles for Potential Immunotherapy of Hepatocellular Carcinoma. Front Bioeng Biotechnol 2021;9:695635. [PMID: 34692650 DOI: 10.3389/fbioe.2021.695635] [Reference Citation Analysis]
32 Brahma MK, Gilglioni EH, Zhou L, Trépo E, Chen P, Gurzov EN. Oxidative stress in obesity-associated hepatocellular carcinoma: sources, signaling and therapeutic challenges. Oncogene 2021. [PMID: 34290399 DOI: 10.1038/s41388-021-01950-y] [Reference Citation Analysis]
33 Juratli MA, Struecker B, Katou S, Morguel MH, Pascher A. [Influence of molecular pathology on oncological surgery of liver and bile duct tumors]. Chirurg 2021;92:1003-10. [PMID: 34519849 DOI: 10.1007/s00104-021-01495-6] [Reference Citation Analysis]
34 Huang C, Zhang C, Sheng J, Wang D, Zhao Y, Qian L, Xie L, Meng Z. Identification and Validation of a Tumor Microenvironment-Related Gene Signature in Hepatocellular Carcinoma Prognosis. Front Genet 2021;12:717319. [PMID: 34899826 DOI: 10.3389/fgene.2021.717319] [Reference Citation Analysis]
35 Wu H, Zhu JQ, Xu XF, Xing H, Wang MD, Liang L, Li C, Jia HD, Shen F, Huang DS, Yang T. Biointerfacing Antagonizing T-Cell Inhibitory Nanoparticles Potentiate Hepatocellular Carcinoma Checkpoint Blockade Therapy. Small 2021;:e2105237. [PMID: 34791793 DOI: 10.1002/smll.202105237] [Reference Citation Analysis]
36 Chandok N, Sirpal S, Yoshida EM. Checkpoint inhibition in hepatocellular carcinoma: Outsmarting the Squid Game. CanLivJ. [DOI: 10.3138/canlivj-2022-0012] [Reference Citation Analysis]
37 Damm R, Pech M, Cavalli P, Haag F, Gylstorff S, Omari J, Thormann M, Seidensticker R, Ricke J, Seidensticker M, Relja B. Correlation of chemokines and growth factors with radiation-induced liver injury after interstitial high dose rate (HDR) brachytherapy of liver metastases. J Cancer Res Clin Oncol 2022. [PMID: 35596772 DOI: 10.1007/s00432-022-04041-x] [Reference Citation Analysis]
38 Li S, Chen S, Dong Z, Song X, Li X, Huang Z, Li H, Huang L, Zhuang G, Lan R, Guo M, Li W, Saw PE, Zhang L. Concurrent silencing of TBCE and drug delivery to overcome platinum-based resistance in liver cancer. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.03.003] [Reference Citation Analysis]
39 Salem R, Gabr A. Transarterial Radioembolization Versus Systemic Treatment for Hepatocellular Carcinoma with Macrovascular Invasion: Analysis of the U.S. National Cancer Database. J Nucl Med 2022;63:57-8. [PMID: 34916247 DOI: 10.2967/jnumed.121.262917] [Reference Citation Analysis]
40 Fidelman N. A Leap from TACE to TACE Potentiated by Immune Response Modulation and Angiogenesis Inhibition for Patients with Intermediate-Stage Hepatocellular Carcinoma: LEAP-012 Phase 3 Randomized Control Trial Protocol. Cardiovasc Intervent Radiol 2021. [PMID: 34853874 DOI: 10.1007/s00270-021-03010-0] [Reference Citation Analysis]
41 Wang X, Yang Z, Meng Z, Sun S. Transforming Commercial Copper Sulfide into Injectable Hydrogels for Local Photothermal Therapy. Gels 2022;8:319. [DOI: 10.3390/gels8050319] [Reference Citation Analysis]
42 Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, Pikarsky E, Zhu AX, Finn RS. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol 2021. [PMID: 34764464 DOI: 10.1038/s41571-021-00573-2] [Reference Citation Analysis]
43 Inoue T, Yoneda M. Updated evidence on the clinical impact of endoscopic radiofrequency ablation in the treatment of malignant biliary obstruction. Dig Endosc 2021. [PMID: 34107114 DOI: 10.1111/den.14059] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
44 Huber TC, Bochnakova T, Koethe Y, Park B, Farsad K. Percutaneous Therapies for Hepatocellular Carcinoma: Evolution of Liver Directed Therapies. J Hepatocell Carcinoma 2021;8:1181-93. [PMID: 34589446 DOI: 10.2147/JHC.S268300] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Hedrich V, Breitenecker K, Djerlek L, Ortmayr G, Mikulits W. Intrinsic and Extrinsic Control of Hepatocellular Carcinoma by TAM Receptors. Cancers (Basel) 2021;13:5448. [PMID: 34771611 DOI: 10.3390/cancers13215448] [Reference Citation Analysis]
46 Jia Q, Zhang Y, Xu B, Liao X, Bu Y, Xu Z, Duan X, Zhang Q. Dual roles of WISP2 in the progression of hepatocellular carcinoma: implications of the fibroblast infiltration into the tumor microenvironment. Aging (Albany NY) 2021;13:21216-31. [PMID: 34497155 DOI: 10.18632/aging.203424] [Reference Citation Analysis]
47 Wang B, Cai H, Waterhouse GIN, Qu X, Yang B, Lu S. Carbon Dots in Bioimaging, Biosensing and Therapeutics: A Comprehensive Review. Small Science. [DOI: 10.1002/smsc.202200012] [Reference Citation Analysis]
48 Haber PK, Puigvehí M, Castet F, Lourdusamy V, Montal R, Tabrizian P, Buckstein M, Kim E, Villanueva A, Schwartz M, Llovet JM. Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020). Gastroenterology 2021;161:879-98. [PMID: 34126063 DOI: 10.1053/j.gastro.2021.06.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
49 Guo M, Qi F, Rao Q, Sun J, Du X, Qi Z, Yang B, Xia J. Serum LAG-3 Predicts Outcome and Treatment Response in Hepatocellular Carcinoma Patients With Transarterial Chemoembolization. Front Immunol 2021;12:754961. [PMID: 34691076 DOI: 10.3389/fimmu.2021.754961] [Reference Citation Analysis]
50 Liu JJ, Xin B, Du L, Chen L, Long Y, Feng GS. Pharmaceutical SH2 domain-containing protein tyrosine phosphatase 2 inhibition suppresses primary and metastasized liver tumors by provoking hepatic innate immunity. Hepatology 2022. [PMID: 35503714 DOI: 10.1002/hep.32555] [Reference Citation Analysis]
51 Yue H, Gou L, Tang Z, Liu Y, Liu S, Tang H. Construction of pH-responsive nanocarriers in combination with ferroptosis and chemotherapy for treatment of hepatocellular carcinoma. Cancer Nano 2022;13. [DOI: 10.1186/s12645-022-00111-4] [Reference Citation Analysis]
52 Rizzo A, Ricci AD, Brandi G. Combining immune checkpoint inhibitors with locoregional therapies in hepatocellular carcinoma. Expert Review of Precision Medicine and Drug Development 2022;7:1-3. [DOI: 10.1080/23808993.2022.2020091] [Reference Citation Analysis]
53 Jacquelot N, Seillet C, Souza-Fonseca-Guimaraes F, Sacher AG, Belz GT, Ohashi PS. Natural Killer Cells and Type 1 Innate Lymphoid Cells in Hepatocellular Carcinoma: Current Knowledge and Future Perspectives. Int J Mol Sci 2021;22:9044. [PMID: 34445750 DOI: 10.3390/ijms22169044] [Reference Citation Analysis]
54 Rizzo A. Locoregional treatments plus immunotherapy in hepatocellular carcinoma: where do we stand? Future Oncol 2022. [PMID: 35193371 DOI: 10.2217/fon-2021-1623] [Reference Citation Analysis]
55 Harkus U, Wankell M, Palamuthusingam P, Mcfarlane C, Hebbard L. Immune checkpoint inhibitors in HCC: cellular, molecular and systemic data. Seminars in Cancer Biology 2022. [DOI: 10.1016/j.semcancer.2022.01.005] [Reference Citation Analysis]
56 Brown ZJ, Hewitt DB, Pawlik TM. Combination therapies plus transarterial chemoembolization in hepatocellular carcinoma: a snapshot of clinical trial progress. Expert Opin Investig Drugs 2021;:1-13. [PMID: 34788184 DOI: 10.1080/13543784.2022.2008355] [Reference Citation Analysis]
57 Jung JM, Kim SH, Giang Phan VH, Thambi T, Lee DS. Therapeutic effects of boronate ester cross-linked injectable hydrogels for the treatment of hepatocellular carcinoma. Biomater Sci 2021;9:7275-86. [PMID: 34609388 DOI: 10.1039/d1bm00881a] [Reference Citation Analysis]
58 Rivoltini L, Bhoori S, Camisaschi C, Bergamaschi L, Lalli L, Frati P, Citterio D, Castelli C, Mazzaferro V. Y90-radioembolisation in hepatocellular carcinoma induces immune responses calling for early treatment with multiple checkpoint blockers. Gut 2022:gutjnl-2021-326869. [PMID: 35508369 DOI: 10.1136/gutjnl-2021-326869] [Reference Citation Analysis]
59 Lafnoune A, Lee S, Heo J, Daoudi K, Darkaoui B, Chakir S, Cadi R, Mounaji K, Shum D, Seo H, Oukkache N. Anti-Cancer Activity of Buthus occitanus Venom on Hepatocellular Carcinoma in 3D Cell Culture. Molecules 2022;27:2219. [DOI: 10.3390/molecules27072219] [Reference Citation Analysis]
60 Renne SL, Sarcognato S, Sacchi D, Guido M, Roncalli M, Terracciano L, Di Tommaso L. Hepatocellular carcinoma: a clinical and pathological overview. Pathologica 2021;113:203-17. [PMID: 34294938 DOI: 10.32074/1591-951X-295] [Reference Citation Analysis]
61 Wang Y, Zhao Q, Zhao B, Zheng Y, Zhuang Q, Liao N, Wang P, Cai Z, Zhang D, Zeng Y, Liu X. Remodeling Tumor-Associated Neutrophils to Enhance Dendritic Cell-Based HCC Neoantigen Nano-Vaccine Efficiency. Adv Sci (Weinh) 2022;9:e2105631. [PMID: 35142445 DOI: 10.1002/advs.202105631] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
62 Mínguez B, Lledó-Navarro JL. Foreword. Clin Drug Investig 2022. [PMID: 35532834 DOI: 10.1007/s40261-022-01148-4] [Reference Citation Analysis]
63 Guiu B, Garin E, Allimant C, Edeline J, Salem R. TARE in Hepatocellular Carcinoma: From the Right to the Left of BCLC. Cardiovasc Intervent Radiol 2022. [PMID: 35149884 DOI: 10.1007/s00270-022-03072-8] [Reference Citation Analysis]
64 Han JW, Yoon SK. Immune Responses Following Locoregional Treatment for Hepatocellular Carcinoma: Possible Roles of Adjuvant Immunotherapy. Pharmaceutics 2021;13:1387. [PMID: 34575463 DOI: 10.3390/pharmaceutics13091387] [Reference Citation Analysis]
65 Wang Y, Li P, Mao S, Mo Z, Cao Z, Luo J, Zhou M, Liu X, Zhang S, Yu L. Exosome CTLA-4 Regulates PTEN/CD44 Signal Pathway in Spleen Deficiency Internal Environment to Promote Invasion and Metastasis of Hepatocellular Carcinoma. Front Pharmacol 2021;12:757194. [PMID: 34744733 DOI: 10.3389/fphar.2021.757194] [Reference Citation Analysis]
66 Zane KE, Makary MS. Locoregional Therapies for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Cancers (Basel) 2021;13:5430. [PMID: 34771593 DOI: 10.3390/cancers13215430] [Reference Citation Analysis]
67 Yao J, Zhu X, Wu Z, Wei Q, Cai Y, Zheng Y, Hu X, Hu H, Zhang X, Pan H, Zhong X, Han W. Efficacy and safety of PD-1 inhibitor combined with antiangiogenic therapy for unresectable hepatocellular carcinoma: A multicenter retrospective study. Cancer Med 2022. [PMID: 35403359 DOI: 10.1002/cam4.4747] [Reference Citation Analysis]
68 Zhang P, Li Y, Tang W, Zhao J, Jing L, Mchugh KJ. Theranostic nanoparticles with disease-specific administration strategies. Nano Today 2022;42:101335. [DOI: 10.1016/j.nantod.2021.101335] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]